Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rank in Stocks #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Share Price
$207.15
Market Cap
$366.28B
Change (1 day)
0.99%
Change (1 year)
2.91%
Country
US
Trade AbbVie Inc. (ABBV)

Category

Revenue for AbbVie Inc. (ABBV)
Revenue in Dec 2025 TTM: $61.16B
According to AbbVie Inc. latest financial reports the company's current revenue (TTM) is $61.16B. In 2024 the company made a revenue of $56.33B an increase over the revenue in the year 2023 that was $54.32B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbbVie Inc. from 2009 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $61.16B 0.00%
2025 $61.16B 8.57%
2024 $56.33B 3.71%
2023 $54.32B -6.44%
2022 $58.05B 3.30%
2021 $56.20B 22.69%
2020 $45.80B 37.69%
2019 $33.27B 1.57%
2018 $32.75B 16.08%
2017 $28.22B 10.06%
2016 $25.64B 12.16%
2015 $22.86B 14.52%
2014 $19.96B 6.23%
2013 $18.79B 2.23%
2012 $18.38B 5.37%
2011 $17.44B 11.55%
2010 $15.64B 10.02%
2009 $14.21B 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$65.18B 6.57%
US
$58.74B -3.96%
GB
$94.19B 54.01%
US
$56.15B -8.19%
CH
$65.01B 6.30%
US